thalidomide has been researched along with Escherichia coli Infections in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Escherichia coli Infections: Infections with bacteria of the species ESCHERICHIA COLI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide, an agent which inhibits biosynthesis of tumor necrosis factor alpha (TNF-alpha) and which is used to treat a variety of chronic inflammatory conditions, was investigated as therapy for experimental sepsis." | 7.72 | Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide. ( Dontas, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Kostomitsopoulos, N; Perrea, D; Poulaki, H, 2003) |
| "Thalidomide, an agent which inhibits biosynthesis of tumor necrosis factor alpha (TNF-alpha) and which is used to treat a variety of chronic inflammatory conditions, was investigated as therapy for experimental sepsis." | 3.72 | Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide. ( Dontas, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Kostomitsopoulos, N; Perrea, D; Poulaki, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giamarellos-Bourboulis, EJ | 1 |
| Poulaki, H | 1 |
| Kostomitsopoulos, N | 1 |
| Dontas, I | 1 |
| Perrea, D | 1 |
| Karayannacos, PE | 1 |
| Giamarellou, H | 1 |
1 other study available for thalidomide and Escherichia coli Infections
| Article | Year |
|---|---|
Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide.
Topics: Animals; Bacteremia; Cytokines; Escherichia coli Infections; Female; Humans; Immunosuppressive Agent | 2003 |